A novel RRGW derived peptide is a promising inhibitor of BoNT/A

References

• Kumaran D, Rawat R, Ahmed SA, Swaminathan S. Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog. 2008;4(9):e1000165.
   PubMed Web of Science ®Google Scholar
• Hale M, Oyler G, Swaminathan S, Ahmed SA. Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J Biol Chem. 2011;286(3):1802–1811.
   PubMed Web of Science ®Google Scholar
• Flores A, Ramirez-Franco J, Desplantes R, Debreux K, Ferracci G, Wernert F, Blanchard M-P, Maulet Y, Youssouf F, Sangiardi M, et al. Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B. Proc Natl Acad Sci U S A. 2019;116(36):18098–18108.
   PubMed Web of Science ®Google Scholar
• Whitemarsh RCM, Strathman MJ, Chase LG, Stankewicz C, Tepp WH, Johnson EA, Pellett S. Novel application of human neurons derived from induced pluripotent stem cells for highly sensitive botulinum neurotoxin detection. Toxicol Sci. 2012;126(2):426–435.
   PubMed Web of Science ®Google Scholar
• Eubanks LM, Hixon MS, Jin W, Hong S, Clancy CM, Tepp WH, Baldwin MR, Malizio CJ, Goodnough MC, Barbieri JT, et al. An in vitro and in vivo disconnect uncovered through high-throughput identification of botulinum neurotoxin A antagonists. Proc Natl Acad Sci U S A. 2007;104(8):2602–2607.
   PubMed Web of Science ®Google Scholar
• Coté TR, Mohan AK, Polder JA, Walton MK, Braun MM. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases. J Am Acad Dermatol. 2005;53(3):407–415.
   PubMed Web of Science ®Google Scholar
• Dong M, Yeh F, Tepp WH, Dean C, Johnson EA, Janz R, Chapman ER. SV2 is the protein receptor for botulinum neurotoxin A. Science. 2006;312(5773):592–596.
   PubMed Web of Science ®Google Scholar
• Lin L, Olson ME, Eubanks LM, Janda KD. Strategies to Counteract Botulinum Neurotoxin A: Nature’s Deadliest Biomolecule. Acc Chem Res. 2019;52(8):2322–2331.
   PubMed Web of Science ®Google Scholar
• Bremer PT, Adler M, Phung CH, Singh AK, Janda KD. Newly Designed Quinolinol Inhibitors Mitigate the Effects of Botulinum Neurotoxin A in Enzymatic, Cell-Based, and ex Vivo Assays. J Med Chem. 2017;60(1):338–348.
   PubMed Web of Science ®Google Scholar
• Ruthel G, Burnett JC, Nuss JE, Wanner LM, Tressler LE, Torres-Melendez E, Sandwick SJ, Retterer CJ, Bavari S. Post-intoxication inhibition of botulinum neurotoxin serotype A within neurons by small-molecule, non-peptidic inhibitors. Toxins (Basel)).), 2011;3(3):207–217.
   PubMed Web of Science ®Google Scholar
• Farrow B, Wong M, Malette J, Lai B, Deyle KM, Das S, Nag A, Agnew HD, Heath JR. Epitope targeting of tertiary protein structure enables target-guided synthesis of a potent in-cell inhibitor of botulinum neurotoxin. Angew Chem Int Ed Engl. 2015;54(24):7114–7119.
   PubMed Web of Science ®Google Scholar
• Minnow YVT, Goldberg R, Tummalapalli SR, Rotella DP, Goodey NM. Mechanism of inhibition of botulinum neurotoxin type A light chain by two quinolinol compounds. Arch Biochem Biophys. 2017;618:15–22.
   PubMed Web of Science ®Google Scholar
• Kiris E, Burnett JC, Kane CD, Bavari S. Recent advances in botulinum neurotoxin inhibitor development. Curr Top Med Chem. 2014;14(18):2044–2061.
   PubMed Web of Science ®Google Scholar
• Kumar G, Kumaran D, Ahmed SA, Swaminathan S. Peptide inhibitors of botulinum neurotoxin serotype A: design, inhibition, cocrystal structures, structure-activity relationship and pharmacophore modeling. Acta Crystallogr D Biol Crystallogr. 2012;68(Pt 5):511–520.
   PubMedGoogle Scholar
• Ahmed SA, Byrne MP, Jensen M, Hines HB, Brueggemann E, Smith LA. Enzymatic autocatalysis of botulinum A neurotoxin light chain. J Protein Chem. 2001;20(3):221–231.
   PubMedGoogle Scholar
• Miyashita S-I, Zhang J, Zhang S, Shoemaker CB, Dong M. Delivery of single-domain antibodies into neurons using a chimeric toxin-based platform is therapeutic in mouse models of botulism. Sci Transl Med. 2021;13(575):eaaz4197.
   PubMed Web of Science ®Google Scholar
• Aoki KR. A comparison of the safety margins of botulinum neurotoxin serotypes A, B, and F in mice. Toxicon. 2001;39(12):1815–1820.
   PubMed Web of Science ®Google Scholar
• Bremer PT, Hixon MS, Janda KD. Benzoquinones as inhibitors of botulinum neurotoxin serotype A. Bioorg Med Chem. 2014;22(15):3971–3981.
   PubMed Web of Science ®Google Scholar
• Lin L, et al. Transformation of a metal chelate into a "catch and anchor" inhibitor of botulinum a protease. Int J Mol Sci. 2023;24(5):4303.
   PubMed Web of Science ®Google Scholar
• Patel EN, Turner LD, Hixon MS, Janda KD. Identification of Slow-Binding Inhibitors of the BoNT/A Protease. ACS Med Chem Lett. 2022;13(4):742–747.
   PubMed Web of Science ®Google Scholar
• Ho M, Goh C-H, Brothers MC, Wang S, Young RL, Ou Y, Lui JN-M, Kalafatis M, Lan X, Wolf AE, et al. Glycine insertion at protease cleavage site of SNAP25 resists cleavage but enhances affinity for botulinum neurotoxin serotype A. Protein Sci. 2012;21(3):318–326.
   PubMed Web of Science ®Google Scholar
• Bellmann-Sickert K, Beck-Sickinger AG. Peptide drugs to target G protein-coupled receptors. Trends Pharmacol Sci. 2010;31(9):434–441.
   PubMed Web of Science ®Google Scholar